No Data
No Data
guizhou sanli pharmaceutical co.,ltd. (603439.SH): Guoshenghaitong private enterprise high-quality development fund's shareholding has decreased to below 5%.
On September 25, Gelonhui reported that Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH) disclosed that on September 24, 2024, Guoshenghaitong private enterprise high-quality development fund reduced its holdings of the company's unrestricted circulating shares by 9,900 shares through centralized competitive bidding on the Shanghai Stock Exchange. The reduction accounted for 0.002416% of the company's total share capital. After this equity change, Guoshenghaitong private enterprise high-quality development fund holds 20,490,100 shares of the company, accounting for 4.999997% of the total share capital, no longer a shareholder holding more than 5% of the company.
guizhou sanli pharmaceutical co.,ltd. (603439.SH) intends to acquire 40% equity of its subsidiary sankang partnership.
Guizhou Sanli (603439.SH) announced that the company intends to acquire Guizhou Healthy Agricultural Traditional Chinese Medicine Industry Development Group...
Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH): Subsidiary plans to increase capital with related parties in Chengdu Dimension Era.
On September 20, Guizhou Sanli (603439.SH) announced that in order to promote the company's business development, its wholly-owned subsidiary Sanli Health intends to increase capital in Chengdu Dimensional Times jointly with Chuangjian Yongsheng, Yaozunbao, and Changan Technology, with a total capital increase of 70 million yuan. This transaction is based on the registered capital as the price basis. After the completion of this transaction, the registered capital of Chengdu Dimensional Times will increase from 10 million yuan to 80 million yuan, of which Sanli Health, a wholly-owned subsidiary of the company, will contribute 20 million yuan and hold a 25.00% stake, while Chuangjian Yongsheng will contribute 34.8 million yuan and hold a...
Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) Could Be Riskier Than It Looks
Guizhou Sanli Pharmaceutical Plans Up to 120-Million-Yuan Share Buyback
Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH): The controlling shareholder voluntarily promises not to reduce its shareholding in the company within 18 months.
On September 12, Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH) announced that, based on the confidence in the company's future prospects and long-term value, and to enhance the confidence of investors and effectively protect the rights and interests of investors and the stability of the capital markets, Mr. Zhang Hai, the controlling shareholder and actual controller of the company, voluntarily pledged not to actively reduce his directly held shares of the company within 18 months from September 13, 2024 (i.e. from September 13, 2024 to March 12, 2026) in any way. As of the date of this announcement, Mr. Zhang Hai holds 167,668,440 shares of the company, accounting for
No Data
No Data